Pierre‐Yves Michellys

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

Yong Jia, Cai‐Hong Yun, Eunyoung Park et al. · Nature · 2016 · 851 citations · Full text

Molecular Pharmacology, Medicine, Pharmacology +4

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama et al. · Cancer Discovery · 2014 · 820 citations · Full text

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 405 citations · Full text

Chemoprevention Strategy, Pharmacotherapy, Structure–activity Relationships +21

Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex

Dirksen E. Bussiere, Lili Xie, Honnappa Srinivas et al. · Nature Chemical Biology · 2019 · 243 citations

Signal Transduction, Molecular Research, Molecular Regulation +10

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain

Christian C. Lee, Yong Jia, Nanxin Li et al. · Biochemical Journal · 2010 · 175 citations